Plinabulin – 5 mg

Brand:
Cayman
CAS:
714272-27-2
Storage:
-20
UN-No:
Non-Hazardous - /

Plinabulin is a diketopiperazine that induces complete tubulin depolymerization in human umbilical vein endothelial cells (HUVECs) when used at a concentration of 2 μM.{39590} It induces HUVEC monolayer permeability, a marker of vascular collapse, in vitro. Plinabulin is cytotoxic against a panel of cancer cell lines, including the multidrug-resistant MES-SA/Dx5 and HL-60/MX2 cell lines (IC50s = 4.3-18 nM). It induces cell death in patient-derived multiple myeloma cells without affecting viability of peripheral blood mononuclear cells (PBMCs) via inhibition of tubule formation and cell migration as well as induction of mitotic arrest and apoptosis in a JNK-dependent manner.{39591} Plinabulin (7.5 mg/kg) reduces tumor size and increases survival in a MM.1S multiple myeloma mouse xenograft model. Formulations containing plinabulin are under clinical investigation for the treatment of solid tumors and lymphomas.  

 

Available on backorder

SKU: 24190 - 5 mg Category:

Description

A tubulin depolymerizing agent; induces complete tubulin depolymerization in HUVECs (2 μM); induces HUVEC monolayer permeability in vitro; cytotoxic against a panel of cancer cell lines (IC50s = 4.3-18 nM); induces cell death in patient-derived multiple myeloma cells via inhibition of tubule formation and cell migration as well as induction of mitotic arrest and apoptosis in a JNK-dependent manner; reduces tumor size and increases survival in a MM.1S multiple myeloma mouse xenograft model (7.5 mg/kg) ,


Formal name: 3Z-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene]-6Z-(phenylmethylene)-2,5-piperazinedione

Synonyms:  NPI-2358

Molecular weight: 336.4

CAS: 714272-27-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Multidrug Resistance